Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma

Inclusion Criteria:

* Histologically or cytologically confirmed symptomatic multiple myeloma:

  * Stage II or III disease
  * Relapsed or refractory disease after \>= 2 courses of prior chemotherapy
* Measurable levels of monoclonal protein (M protein) \> 1.0 g/dL by serum protein electrophoresis OR \> 200 mg of monoclonal light chain by 24-hour urine protein electrophoresis
* Measurable bone disease, defined as \>= 1 unidimensionally measurable lesion (longest diameter to be recorded) \>= 20 mm with conventional techniques OR \>= 10 mm with spiral CT scan (for patients with lytic bone disease)
* No known brain metastases
* ECOG performance status (PS) 0-2 OR Karnofsky PS 70-100%

  * Patients with PS of 3 are eligible if it is due to pain that is likely to improve with treatment
* Life expectancy \> 6 months
* No known HIV positivity
* No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
* No active infections requiring oral or intravenous antibiotics within the past week
* No proteinuria (i.e., albuminuria) \> 1,000 mg/24 hours unless related to the diagnosis of multiple myeloma

  * Patients with light chain (i.e., "Bence-Jones") proteinuria are still eligible if the non-light chain component of protein is \< 1,000 mg/24 hours
* No serious nonhealing wound or ulcer
* No blood pressure \> 150/90 mm Hg (even with medication)
* No significant traumatic injury within the past 28 days
* No clinically significant peripheral vascular disease
* No evidence of bleeding diathesis or coagulopathy
* No unstable angina or myocardial infarction within the past 6 months
* No stroke within the past 6 months
* No New York Heart Association class III or IV heart failure
* No secondary malignancy within the past 2 years except squamous cell or basal cell carcinoma of the skin or carcinoma in situ of the cervix
* Hemoglobin \> 9 g/dL (may be supported by transfusion or growth factors)
* WBC \>= 2,000/mm\^3
* Absolute neutrophil count \>= 1,000/mm\^3
* Platelet count \>= 75,000/mm\^3
* Bilirubin =\< 2.5 mg/dL
* At least 4 weeks since prior chemotherapy or radiotherapy and recovered
* More than 7 days since prior minor surgical procedures, fine-needle aspirations, or core biopsies:

More than 24 hours since prior bone marrow biopsy or central veinous access placement

* More than 28 days since prior major surgical procedure or open biopsy
* At least 4 weeks since prior and no concurrent participation in another experimental drug study
* Prior autologous peripheral blood stem cell transplantation allowed
* No prior lenalidomide
* Concurrent full-dose anticoagulants allowed provided all of the following criteria are met:

  * No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)
  * No thrombocytopenia requiring transfusion
  * Platelet count \> 75,000/mm3
  * INR 2-3 and stable
* No concurrent major surgery
* No concurrent sargramostim (GM-CSF)
* No other concurrent investigational agents
* No other concurrent anticancer agents or therapies
* AST and ALT =\< 5 times upper limit of normal
* Creatinine \< 2.5 mg/dL
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use 2 methods of effective contraception 4 weeks before, during, and 4 weeks after completion of study treatment
* No history of allergic reactions attributed to compounds of similar chemical or biological composition to lenalidomide and/or bevacizumab or other agents used in the study